DE602006015338D1 - Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen - Google Patents

Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen

Info

Publication number
DE602006015338D1
DE602006015338D1 DE602006015338T DE602006015338T DE602006015338D1 DE 602006015338 D1 DE602006015338 D1 DE 602006015338D1 DE 602006015338 T DE602006015338 T DE 602006015338T DE 602006015338 T DE602006015338 T DE 602006015338T DE 602006015338 D1 DE602006015338 D1 DE 602006015338D1
Authority
DE
Germany
Prior art keywords
cholinerge
enhancer
diseases
combine
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006015338T
Other languages
German (de)
English (en)
Inventor
Alfred Maelicke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galantos Pharma GmbH
Original Assignee
Galantos Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05020721A external-priority patent/EP1777222A1/en
Application filed by Galantos Pharma GmbH filed Critical Galantos Pharma GmbH
Publication of DE602006015338D1 publication Critical patent/DE602006015338D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE602006015338T 2005-09-22 2006-09-22 Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen Active DE602006015338D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05020721A EP1777222A1 (en) 2005-09-22 2005-09-22 Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US78024306P 2006-03-07 2006-03-07
PCT/EP2006/009220 WO2007039138A1 (en) 2005-09-22 2006-09-22 Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Publications (1)

Publication Number Publication Date
DE602006015338D1 true DE602006015338D1 (de) 2010-08-19

Family

ID=40506504

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006015338T Active DE602006015338D1 (de) 2005-09-22 2006-09-22 Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen

Country Status (4)

Country Link
JP (1) JP2009508903A (ja)
AT (1) ATE473219T1 (ja)
CY (1) CY1110822T1 (ja)
DE (1) DE602006015338D1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014016430A1 (en) * 2012-07-27 2014-01-30 Neurodyn Life Sciences Inc. Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100195399B1 (ko) * 1987-05-04 1999-06-15 보니데이비스 알쯔하이머 병 치료용 의약
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
JP2003529602A (ja) * 2000-03-31 2003-10-07 ザノヒェミア・ファルマツォイティカ・アーゲー ガランタミンの新規誘導体および類似体
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Also Published As

Publication number Publication date
ATE473219T1 (de) 2010-07-15
CY1110822T1 (el) 2015-06-10
JP2009508903A (ja) 2009-03-05

Similar Documents

Publication Publication Date Title
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE540941T1 (de) 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
NL1026203A1 (nl) Verbindingen toepasbaar voor de behandeling van ziekten.
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
ATE517877T1 (de) Neue arzneimittel zur behandlung von atemwegserkrankungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006002608D1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
DE602006015338D1 (de) Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen